SCHEMBL30197341

SCHEMBL30197341

Cc1nc2cc(F)c(N)cc2o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
GAA P10253 2/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.37
ALDH1A1 P00352 3/20 0.36
POLB P06746 2/20 0.36
RAB9A P51151 5/20 0.35
NPC1 O15118 4/20 0.35
STAT1 P42224 1/20 0.35
BACE1 P56817 4/20 0.33
KDM4E B2RXH2 4/20 0.33
MAPT P10636 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
BMPR1B O00238 1/20 0.33
RIPK2 O43353 1/20 0.33
STK16 O75716 1/20 0.33
STK10 O94804 1/20 0.33
MAP4K4 O95819 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857363 1.00 L3MBTL1 (0.41) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL8221475 0.93 L3MBTL1 (0.41) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL3180303 0.84 GAA (0.46) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL8251550 0.81 GAA (0.43) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL10885994 0.81 TERT (0.45) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL25105686 0.78 GAA (0.41) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL19914264 0.78 LRRK2 (0.42) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL14561648 0.78 CHRNB2 (0.44) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL31344803 0.78 MAPT (0.41) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2
SCHEMBL30995441 0.78 GAA (0.41) L3MBTL1GAACHRNB2CHRNA4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 US disclosed
EP-4149937-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI Foundation, Inc. (US) 2023-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC5, ABCC1 L3MBTL1 4705/4885GAA 952/4885CHRNB2 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.